Northwest Biotherapeutics

About:

Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.

Website: http://nwbio.com

Twitter/X: NorthwestBio

Top Investors: Woodford Investment Management

Description:

Northwest Biotherapeutics is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies.

Total Funding Amount:

$169M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Bethesda, Maryland, United States

Founded Date:

1998-01-01

Contact Email:

media(AT)nwbio.com

Founders:

Alton L. Boynton

Number of Employees:

11-50

Last Funding Date:

2021-11-22

IPO Status:

Public

Industries:

© 2025 bioDAO.ai